Cara Therapeutics, Inc. (LON: 0HTC)
London
· Delayed Price · Currency is GBP · Price in USD
4.560
-0.085 (-1.83%)
Jan 23, 2025, 2:34 PM BST
Cara Therapeutics Revenue
Cara Therapeutics had revenue of $2.56M USD in the quarter ending September 30, 2024, a decrease of -47.47%. This brings the company's revenue in the last twelve months to $8.69M, down -59.08% year-over-year. In the year 2023, Cara Therapeutics had annual revenue of $20.97M, down -49.92%.
Revenue (ttm)
$8.69M
Revenue Growth
-59.08%
P/S Ratio
n/a
Revenue / Employee
$157.93K
Employees
55
Market Cap
17.74M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.97M | -20.90M | -49.92% |
Dec 31, 2022 | 41.87M | 18.84M | 81.81% |
Dec 31, 2021 | 23.03M | -112.05M | -82.95% |
Dec 31, 2020 | 135.08M | 115.20M | 579.28% |
Dec 31, 2019 | 19.89M | 6.42M | 47.64% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Cara Therapeutics News
- 16 days ago - CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA - Business Wire
- 21 days ago - Bullish Wednesday For Marijuana Stocks - Cara Therapeutics, MPX International Among Top Gainers - Benzinga
- 22 days ago - Cara shares jump 32% following reverse stock split - Seeking Alpha
- 27 days ago - Cara Therapeutics announces 1-for-12 reverse stock split to regain Nasdaq compliance - Seeking Alpha
- 27 days ago - Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - GlobeNewsWire
- 5 weeks ago - $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc. - CARA - PRNewsWire
- 5 weeks ago - CARA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cara Therapeutics, Inc. Is Fair to Shareholders - Business Wire
- 5 weeks ago - Cara in all-stock merger deal with Tvardi - Seeking Alpha